Harrow Health, Inc. (NASDAQ:HROW) is set to announce second quarter earning results on Monday 10th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, HROW to report 2Q20 loss of $ 0.1 per share from revenue of $ 5.70 million.
For the full year, analysts anticipate top line of $ 35.84 million, while looking forward to loss of $ 0.77 per share bottom line.
Previous Quarter Performance
Harrow Health, Inc. unwinded loss for the first quarter of $ 0.50 per share, from the revenue of $ 11.82 million. The quarterly revenues fell 2.72 percent compared with the same quarter last year. Street analysts expected Harrow Health, Inc. to report loss of $ 0.25 per share on revenue of $ 11.77 million for the first quarter. The bottom line results missed street analysts by $ 0.25 or 100 percent, at the same time, top line results outshined analysts by $ 0.05 million or 0.42 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Harrow Health, Inc.
Stock Performance
According to the previous trading day, closing price of HROW was $ 5.87, representing a 76.28 % increase from the 52 week low of $ 3.33 and a 25.88 % decrease over the 52 week high of $ 7.92.
The company has a market capital of $ 150.38 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”HROW” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Harrow Health, Inc. will be hosting a conference call at 5:00 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.harrowinc.com
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings.
